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CHAPTER I 
INTRODUCTION 
SOME GENERAL AND BIOLOGICAL AND PHYSICAL 
CHARACTERISTICS OF HERPESVIRUSES 
Every species of animal is suspected of harboring at least one 
herpesvirus. However, since herpesviruses are often difficult to cul­
ture , only about twenty viruses have been reported to be in the herpes­
virus group, which includes animal and human viruses (16, 25, 34). 
Melnick, et _al. (1964) subdivided the herpesviruses into subgroups A 
and B. Group A viruses are released readily from infected cells, 
whereas Group B viruses tend to remain cell-associated (17, 34). 
Group A viruses include Herpesvirus hominls (formerly herpes 
simplex virus) and several similar animal viruses. Group B viruses 
include the varicella-zoster virus (chicken pox in children; shingles 
in adults), cytomegalovirus, which causes a fatal pneumonia of infants, 
and several other human and animal viruses (34). 
Herpesviruses are relatively large viruses with an overall 
size estimated between 140 and 250 nm (6, 8, 34), with an average size 
of 180 to 200 nm (8). The virus is enclosed by a lipid-rich membrane 
or envelope which is apparently of host cell origin (6, 8) and which 
accounts for the overall particle size. Because of essential lipids 
in the envelope, herpesviruses are inactivated by ether or chloroform 
(8, 12, 34). Group A viruses can obtain their envelopes at the nuclear 
membrane but may add additional membranes at the cell surface (6). 
Serological studies show that anti-host cell antibodies (e.g., rabbit 
anti-HeLa) will agglutinate only enveloped viruses grown in that parti­
cular cell line (HeLa). Anti-herpesvirus antibodies agglutinate mostly 
unenveloped viruses (8, 33). Therefore, the envelope may serve to 
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mask the antigenic determinants. Both enveloped and non-enveloped 
viruses are released during Infection, but enveloped particles attach 
to host cells more readily and, once attached, have a much higher via­
bility or infectlvlty than do non-enveloped viruses. It is possible 
that non-enveloped viruses are sensitive to enzymes which may enter 
through holes that appear to be in the capsomeres (structural subunits) 
(7). 
Herpesvirus deoxyribonucleic acid (DNA) is double stranded 
with a molecular weight ranging from 54 to 92 x 10̂  daltons (6), 
According to current quantitative methods, herpesvirus DNA is estimated 
to contain enough Information to specify the sequence of up to 140,000 
amino acids. Assuming that genes are not duplicated, only 10 to 20% 
of the total genetic information is expressed in tissue culture. Com­
pared to other viruses, herpesviruses contain large amounts of genetic 
information for viruses of their size and complexity. Since herpes­
viruses tend to establish lifelong infections in their natural hosts, 
it is thought that the extra genetic information contributes to the 
total infective process in the natural host (16). 
SOm CLINICAL ASPECTS Of GROUP 
A HERPESVIRTTSES 
Clinically, among Group A herpesviruses, it is important to 
note that there is a marked change in virulence when a virus is intro­
duced into an immature or unnatural host. Cytomegalovirus generally 
causes a subclinical Infection in adults, but it is generally fatal for 
infants. Herpesvirus homlnis (HVH) usually causes a mild infection 
in adult humans but causes severe central nervous system damage in 
rabbits and mice (8). 
In man, HVH infections may take several forms and are often 
subclinical. The clinical response is usually a mild vesicular eruption 
of the skin or mucous membranes. The virus may also cause severe ill­
nesses such as stomatitis, Kopsls' varicelliform eruption, meningoence­
phalitis, and a generalized, usually fatal, neonatal disease (12). 
Herpesvirus homlnis has been categorized into two subtypes : 
1 and 2. The type 1 virus strain causes localized recurrent lesions 
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about the lips and mouth. It can also be involved over wider areas of 
skin and cause meningoencephalitis or keratoconjunctivitis (12). The 
type 2 virus strain causes recurrent genital lesions in both men and 
women (21), and frequently causes a systemic infection of infants 
exposed congenitally (transplacentally) or neonatally via herpetic 
lesions in the birth canal. It can also be involved in keratoconjunc­
tivitis or meningoencephalitis (13). 
Ui VITRO STUDIES OF HERPETIC INFECTIONS 
Biological Aspects of In Vitro Herpetic 
Infections 
In vitro studies (i.e., in tissue culture) have yielded much 
information about the infectious process of herpesviruses. In tissue 
culture, HVH has a wide host range, but not all cell lines are equally 
susceptible. Human, simian, rabbit, hamster, mouse, chicken embryo, 
and other cell lines are infected with varying virulence (34). Expo­
sure to HVH induces an abortive infection in dog kidney cells and inhi­
bits the infective process of pseudorabies virus (PRV) in dog kidney 
cells (2). 
The reproductive cycle can be best described in terms of fac­
tors affecting four aspects of the replicative cycle, (i) the duration 
of the eclipse or latent period, (ii) the duration of the replicative 
cycle, (iii) the yield of virus per cell, (iv) the release of virus 
from the infected cells. 
(i) The duration of the latent period varies from 3 to 8 
hours for most herpesviruses. It is affected by the temperature of 
incubation, by the multiplicity of infection, and by prior infection 
of the cells by another mutant strain of virus. Each cell has a mini­
mum latent period when infected with a given virus (e.g., 3 hours for 
PRV in rabbit kidney cells, or 5 hours for HVH in HEp-2 cells). The 
period cannot be shortened by increasing the multiplicity of infection. 
(ii) The duration of the replicative period of herpesviruses 
varies with the virus and the infected cell. It is also affected by 
the multiplicity of infection and the temperature of incubation. The 
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reproductive cycle of HVH in HEp-2 cells varies from 13 to 19 hours; 
at 37°C with an infective dose of 50 plaque-forming units per cell, 
the cycle lasts 17 hours (28). In HeLa at 37°C with an infective dose 
of 5 plaque-forming units per cell, the replicative cycle of HVH lasts 
12 hours (30). 
(iii) The virus yield from infected cells increases exponen­
tially from the end of the latent period until almost the end of 
the replicative cycle. Under optimal conditions the yield of HVH from 
HEp-2 is 10,000 to 100,000 virons per cell, but only about 0.1 to 10% 
of these virons are viable as indicated by their plaque-forming ability 
(28). In HeLa about 40,000 virons per cell are produced, of which 
0.025% are infective as indicated by their plaque-forming ability (31). 
Cells in monolayer usually yield more virus than cells in suspension. 
High virus titers are more readily obtained in rapidly growing cells 
maintained after infection in enriched medium at pH and temperature 
optimal for the particular strain of virus. 
(iv) After infectious herpesvirons appear inside infected 
cells, release is generally slow and temperature-dependent. Herpes­
virus hominis is released more readily from suspended cells at 37°C 
than from cells adhering to glass surfaces or cells incubated at 
34°C. Freezing and thawing or sonication release aggregates of virus 
from infected cells (28). 
Cytopathic effect (CPE), as observed in the light microscope, 
for HVH type 2 (strain 196) is generally "ballooning" and detachment 
of infected cells, with occasional formation of small syncitia 
(giant cells formed by the fusion of several cells). Certain strains 
of PRV normally cause extensive syncitia in infected monolayers of 
cells (25). Many authors have generalized the PRV infective pattern 
to apply to all herpesviruses. Some strains of HVH in the presence of 
specific antibody do form extensive syncitia (11, 25), but strain 196 
(used in this study) forms syncitia only occasionally. 
Observations made with the electron microscope have shown that 
after attachment the viruses are phagocytized into vaculoles in the 
peripheral cytoplasm. The envelope is removed and the naked capsid 
passes into the cytoplasm (6). It is likely that two particle types 
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are necessary to initiate infection. Miyamoto and Morgan (1971) report 
two types of capsids, designated light and dense, based on electron 
density. Light capsids constitute 53%, and dense capsids constitute 
47% of the total number of capsids observed. Shortly after penetra­
tion, dense capsids were observed to be in various stages of disrup­
tion; light capsids remained stable for at least one hour after 
infection. However, after 20 to 30 minutes most of the light capsids 
were devoid of cores. 
It was suggested that the DNA released from the dense capsids 
near the cell surface transcribes a virus-specific messenger ribonu­
cleic acid (mRNA) which codes for an enzyme which renders light cap­
sids permeable to their core contents as they approach the nuclear 
membrane (20). Parental capsids have not been observed in the nucleus. 
Naked capsids appear in the nucleus within 5 to 6 hours after infection 
(18, 23), and enveloped virons appear in the cytoplasm about an hour 
later. Envelopment of the capsid occurs as the virus buds through the 
nuclear membrane or into cytoplasmic vacuoles (6, 23). Late in the 
infection, crystal arrays of capsids appear in the nucleus just prior 
to cell death (6). 
Molecular Aspects of In Vitro 
Herpetic Infection 
During the course of infection, viral mRNA, which is more 
stable than cellular mRNA, is synthesized; this new mRNA is comple­
mentary to viral DNA (7). The activity of DNA metabolism within the 
cell is increased. During the period 2 to 8 hours after infection 
the activity of thymine kinase, thymidylate kinase, DNA polymerase, 
and DNAase Increase; afterward their activities decrease (28). The 
increased activity is due in part to the stabilization of host cell 
enzymes. The HVH-coded enzymes differ from host cell enzymeA and 
poxvirus-coded enzymes in heat stabilitŷ  response to excess substrate, 
response to allosteric reactants, and in Michaelis constant (8, 14). 
Viral protein synthesis increases during the period 3 to 8 hours 
after Infection, after which it declines (28). Host cell protein 
synthesis decreases by one-half within 4 hours. The enzymes which 
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appear early in the infection decrease in activity as the rate of 
assembly of virus particles from accumulated subunits increases. Assem­
bly and active release continue until the cell dies, usually within 
24 hours (8). 
CROWTH CURVE STUDIES WITH 
Purpose 
It was noted by Dr. R. N. Ushijima that when stock pools of 
HVH were prepared in different cell lines there were differences in 
the rates of appearance of CPE and in the peak yields of virus. Pri­
mary rabbit kidney cells showed rapid CPE but yielded low titers of 
virus. HeLa showed delayed CPE but produced higher titers of virus. 
Vero showed rapids CPE and produced the highest virus yield. Since 
these cell lines are used routinely in this laboratory, it was 
decided that growth curve information on HVH in these cell lines 
would be valuable. 
Statement of the Problem 
Experiments were designed to determine the time and rate of 
synthesis of HVH type 2 (strain 196) in the stable cell lines, Vero, 
HeLa, and MAlll (a stable rabbit kidney line) and to determine the 
correlation, if any, between the appearance of CPE and virus production 
by the respective cell lines. 
Experiments were designed to determine the stability of HVH 
type 2 (strain 196) at 37°C and to repeated freeze-thaw cycles, since 
the virus was exposed to both temperature and freeze-thaw degradation 
during preparation. . 
Early trials showed that the titer of the released virus 
remained constant for up to 24 hours after the cells detached from 
the glass culture surface. An experiment was designed to determine 
whether this release of virus by detached cells was active or passive, 
i.e., whether the detached cells were alive or dead. 
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Literature Review 
There appear to be no previous studies reported in the liter­
ature using either Vero or MA.111 with HVH. Both cell lines have been 
used extensively to study RNA viruses (26, 27) and, to some extent, 
SV-40 and adenoviruses (29). HeLa cells have been used extensively 
in studies of HVH. Most studies were either electron microscope 
examinations of the infectious process or biochemical studies of 
Infected cells, but some growth curve information in HeLa cells has 
been reported. Waterson (1968), summarizing Newton and Stoker (1958) 
and Siminoff (1964) , reports yields ranging from 10 to 20 plaque-
forming units per cell—the in vitro plaque method of virus assay in 
tissue culture is analogous to the plaquing of bacteriophage on sus­
ceptible bacteria (4, 5). Peak yields were obtained 16 hours later 
using an Inoculum of 5 plaque-forming units per cell and incubating 
at 37°C. 
The above studies were of interest but were not directly appli­
cable to this study. Three different strains of HVH were used in 
the above studies, none of which were strain 196. The plaque assay 
method was not used in this study and lower multiplicity inocula were 
used. However, similar medium, incubation temperatures, infecting 
methods, and sampling methods were employed. 
Kaplan (1957) conducted stability tests similar to the ones 
done in this study. He conducted both temperature (37°C) and freeze-
thaw stability tests. Although he used the plaque assay method, his 
results were reported in survival percentages and could, therefore, 
be directly compared to the results in this study. Again, there were 
virus strain differences to be considered. From Kaplan's results, 
up to 99% loss of virus was expected after exposure to 37°C for 
24 hours; little loss of virus was expected after up to five freeze-
thaw cycles. 
CHAPTER II 
MATERIALS AND METHODS 
ROUTINE MATERIALS AND METHODS 
General Comments 
Work with tissue culture of animal cells requires more rigor­
ously sterile conditions and quantitatively cleaner glassware than 
does routine bacteriological work. Tissue culture medium Is an Ideal 
medium capable of supporting the growth of many contaminant organisms: 
bacteria, fungi, and mycoplasma. Antibiotics can control contaminating 
organisms of they are few In number and sensitive to the antibiotics 
used. In nearly all laboratories there Is some degree of airborne 
microbial contamination, but If certain precautions are taken, air­
borne contamination can be minimized and controlled by the penicillin 
and streptomycin routinely present In tissue culture medium. 
An Isolation or "sterile" room Is of prime importance. The 
Isolation room should have minimal in-and-out traffic and should be 
equipped with high intensity ultraviolet (U.V.) tubes which are acti­
vated when the room is not in use. A hood with its own U.V. source 
should be in the isolation room to provide additional protection to 
the main work area. Minimal in-and-out traffic allows dust to settle 
in the room and minimizes entry of outside contamination. Therefore, 
all glassware and equipment routinely used for handling cells should 
be stored in the Isolation room. The U.V. serves to inactivate both 
contaminant airborne microbes and any virus that invariably escapes 
when Infected culture containers are opened. 
Sterilization and Decontamination 
Methods 
In addition to maintaining a semi-sterile environment, any 
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equipment which comes Into contact with the cells or cell medium must 
also be sterile. Heat Is the most common means of sterilization. 
The hot air oven, employing a temperature of 180°C, Is useful for 
certain glassware and other materials which can tolerate the heat. 
Since dry heat depends upon desiccation to kill microbes, the time 
needed for sterilization depends upon the object to be sterillzied. 
The autoclave, employing pressurized steam at 121°C, is the choice for 
materials which will tolerate that temperature. A serious disadvantage 
of an autoclave operated by centrally supplied stram (the type at 
the University of Montana) is that the additives in the steam to pre­
vent rust and mineral deposits in the steam lines are toxic to mamma­
lian cells. However, microbial contamination is generally more of a 
problem than toxicity, and methods to minimize autoclave toxicity will 
be discussed as they apply. Filtration is used to sterilize liquids 
which will not tolerate autoclave temperatures. Treatment of filters 
will be discussed below. Ethylene oxide gas is used to sterilize 
plastic objects which cannot be autoclaved. Ultraviolet irradiation 
is used to sterilize certain plastic objects and powdered insoluble 
antibiotics. 
Two filtering systems were available; the Seitz and the 
Millipore. Both employ air pressure or vacuum to force filtrate through 
the filter pad. The major advantage of the Seitz system is its rela­
tively low cost. The Seitz system employs asbestos pads of low poro­
sity, resulting in low flow rates of filtrate. The Seitz filter is 
cleaned after use and rinsed well in distilled water. It is sterilized 
in the hot air oven for 40 minutes (any longer chars the pad) to 
avoid autoclave toxicity. 
The Millipore system, which is more expensive, employs syn­
thetic pads of high porosity and more uniform size, resulting in 
high flow rate of filtrate at low pressure. Millipore pads cannot 
tolerate dry heat and must be autoclaved. 
Both filter systems must be pre-treated with glass-distilled 
water prior to use. The pre-treatment in the Seitz filter helps to 
seal the pad and flushes away any debris from the pad. The Millipore 
pads have a wetting agent which is toxic and must be removed. To 
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remove wetting agent from a 293 mm pad, pass four liters of hot glass-
distilled water (95 to 100°C) through the pad followed by two liters 
of cold (25°C) water. This treatment also seems to remove any auto­
clave toxicity factors. Specific uses of filters will be discussed 
as they apply. 
In addition to routine sterilization of equipment, there is 
the problem of disposal of contaminated (intentional and unintentional) 
materials. Disposable plastic materials can be merely autoclaved. 
Metal containers should be available for storing contaminated materials 
prior to autoclaving. Glassware can be soaked in a dilute bleach 
(Chlorox or Purex) solution for about 10 minutes. In culture bottles, 
this treatment also detaches any cells from the glass, making cleaning 
easier. The pipette disposal jars should also contain a dilute bleach 
solution. Metal caps, plastic caps, and rubber stoppers, which will 
not tolerate bleach or which tend to absorb bleach, can be soaked in 
70% ethanol. 
Cleaning of Glassware 
Glassware must be quantitatively clean to support the life 
of animal cells. Animal cells will not tolerate even the small 
amounts of metal ions normally found in distilled water. Glass-
distilled water must be used in the final rinse of any glassware used 
to grow cells. Â satisfactory supply of glass-distilled water is 
prepared by redistilling tap-distilled water in a Bellco single stage 
distilling unit with a long column. 
The general procedure for washing glassware is as follows : 
1. Rinse in tap water (if it has been soaked in 
bleach. 
2. Wash well in tap water and Detergex brand pow­
dered cleanser (available from Pharmaseal Labo­
ratories, Glendale, California). 
3. Rinse well in tap water. 
4. Soak for about twenty minutes in dilute hydro­
chloric acid in distilled water to remove any 
residual detergent. 
5. Rinse well in distilled water. 
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6. Rinse In glass-dlstllled water If container 
will be used to grow cells or to store medium. 
The general procedure Is modified somewhat to fit the glassware 
being cleaned, but the basic steps are the same. 
Pipettes are drained, the cotton plugs removed, the pipettes 
placed In a Detergex solution and autoclaved for 10 minutes. The 
pipettes are rinsed In a commercial rlnser with tap water for 30 
minutes, placed in an acid rinse for 5 minutes and finally rinsed three 
times in tap-distilled water. After drying, the pipettes are plugged 
with cotton, placed in metal cans and sterilized in the hot air oven 
for 60 minutes. 
Prescription and media bottles are washed according to the 
general procedure and given a final rinse in glass-dlstllled water 
and dried. To minimize autoclave toxicity, a square of Reynolan plas­
tic, cut from Brown-ln-Bag cooking wrap, is used as a gasket under the 
screw cap to minimize the amount of steam which enters the bottle. 
They are autoclaved 10 minutes and put on the drying cycle. 
The Cornwall automatic pipette—an adjustable syringe with 
a one-way siphon—is disassembled and cleaned. The entire components 
receive a final rinse in glass-distilled water, then are wrapped in 
foil and autoclaved 10 minutes on fast exhaust to protect the surgical 
tubing siphon. 
Caps and rubber stoppers are boiled in distilled water. Caps 
are sterilized with the bottle or tube. Rubber stoppers are wrapped 
in foil "candlesticks" and autoclaved 10 minutes on fast exhaust. 
Culture Media and Solutions 
This section describes and discusses media, buffers, and 
other solutions needed to handle cells In tissue culture. To prepare 
versene-trypsin (Table 1), mix part A for 30 to 45 minutes on a mag­
netic stirrer with about half the NaHCÔ  and most of the water; add 
B, then mix for 10 to 15 minutes. The solution is ready to filter 
when clear. Filter through a pad with 0.22 or 0.25 um pores. Dispense 
in 8-ml amounts in screw-capped tubes and store at -70°C. Versene-
trypsin is used to remove monolayered cells from the glass or plastic 
culture surface. 
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Table 1. Chemical Composition of Versene-Trypsln Solution 
Solution Material gm/1. glass-distilled Ĥ O 
A. NaCl 8.0 
KCl 0.4 
Glucose 1.0 
Trypsin 1.5 
B. NaHCO] 0.58 
Versene 0.2 
Phosphate buffered saline (PBS) (Table 2) without and 
Ca ions is designated Pd. Since these cations inhibit the action of 
trypsin, Pd is used Instead of PBS as a wash for monolayered cells 
prior to trypsinizatlon for further passage. The cation-deficient 
buffer is prepared as a lOx stock which is diluted prior to use. The 
resultant Isotonic solution is decanted into 100 ml milk dilution 
bottles and autoclaved 15 minutes with the caps snug to minimize 
mixing with steam. The autoclave is set on slow exhaust cycle. 
Table 2. Chemical Composition of Phosphate Buffered Saline (Dulbecco 
and Vogt, 1954, a fie b) 
Solution Material gm/1. glass-distilled HgO 
A. NaCl 8.0 
KCl 0.2 
Na2HP04 ° THLO 2.15 
KHgPÔ  0.2 
B. MgCl2 * 6H2O 0.1 
CaCl2 0.1 
Minimal Essential Medium (MEM) is prepared from the materials 
listed in Table 3, then filtered through a 0.22 or 0.25 um filter pad. 
Powdered MEM is available through Grand Island Biological Company. 
Potassium penicillin C and streptomycin sulfate are available through 
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Calblochem. Other antibiotics used were Chlorotetracycllne, Kanamycin, 
and Neomycin (antl-mycoplasma agent) and Mycostatln or Nystatin (anti­
fungal agent). These are available from Grand Island Biological 
Company, DIFCO, and others. Product information is provided by the 
suppliers. 
Calf serum can be collected at a local slaughter house. Fetal 
calf blood is preferred, but blood from animals under 8 months of age 
is acceptable. These animals have minimal amounts of gammaglobulins 
In their serum. 
Glass containers are most appropriate for collecting blood 
since they minimize hemolysis. One-gallon mayonnaise jars work well. 
The blood is allowed to clot for several hours, then the clot is 
cut in quarters and allowed to stand overnight in the cold. The serum 
decanted from the jars is put in 250 ml centrifuge tubes, spun at 
2,000 rpm for 15 minutes in an International H9070 size 2 centrifuge 
with a swinging bucket head, and allowed to free wheel to a stop. The 
serum is carefully pipetted from the tubes by suction apparatus. It 
is then cleared by filtration through a filter pad with 4 um pores. 
If filter-sterile serum is desired, it should be reflltered through a 
0.22 or 0.25 um pad. The complement in all sera, sterile or non-
sterile, should be inactivated at 56°C for 30 minutes prior to use. 
In this study, MEM with 3 and 5% calf serum was used. Thirty 
milliliters of 50 ml of serum were added to one liter and designated 
3 and 5%, respectively. 
Serum was stored in 100 and 250 ml amounts in whirl bags if 
non-sterile, and in 500 ml amounts in bottles if sterile. The media 
were prepared in large volumes both for this project and other pro­
jects in the laboratory. Stocks of media containing 5 or 10% serum 
or no serum were prepared monthly and stored at 4°C. 
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Table 3. Composition of the Medium Prepared with Eagle's Minimal 
Essential Medium 
Material Amount of Material Used 
Glass-distilled Ĥ O 1.0 liter 
Commercial powder 9.9 gm 
NaHCO- 1,5 gm (varies) 
Penicillin 100 units/ml 
Streptomycin 100 ug/ml * 
Serum 20 to 200 ml 
Serum may be omitted and sterile serum added as needed. 
The bottles used to store the medium or serum were either 
500 ml bottles which originally contained commercial fetal calf serum 
or 500, 1000, or 1500 ml bottles which originally contained isotonic 
saline and were obtained from a local hospital. 
For general laboratory equipment, John Paul's Cell and Tissue 
Culture (1959) contains basic lists of laboratory apparatus and 
materials as well as a partial list of companies which supply research 
equipment. 
EXPERIMENTAL MATERIALS AND METHODS 
The Virus 
Herpesvirus hominis type 2 (strain 196) was obtained from 
Dr. W. E. Rawls of Baylor University College of Medicine. Stock 
pools of virus were prepared in Vero (stable Green monkey kidney) 
cells. After the culture medium was removed from monolayers of Vero 
7 
cells in 8 oz. prescription bottles containing about 1 x 10 cells, 
1.6 to 4.0 X 10̂  TCID units of virus in 1 ml culture fluid were 
allowed to adsorb to the cells for one hour at 37°C. At the end of 
one hour, 15 to 20 ml of MEM with 3% calf serum were added to the 
bottle. After 30 to 36 hours, or when most of the cells had detached 
from the glass, the cultures were frozen and thawed twice to disrupt 
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the cells and to release cell-associated virus. The cellular debris 
was pelletted In an international H9070 size 2 centrifuge at 1,000 rpm 
for 10 minuteso The supernatant culture fluid was collected and stored 
In flame-sealed glass ampules In 1-ml amounts at -70°C until use. The 
stock pool was tltered by pooling two ampules of virus and titration 
by the 50% Tissue Culture Infective Dose (TCID̂ Q) method. 
The TCID̂ Q by the Mlcrotiter Method̂  
Special materials used for this method were Falcon 3040 Micro-
test II tissue culture plates obtained from Falcon Plastics, Oxnard, 
California; Mlcrodlluters (0.05 ml volume), available from Cooke 
Engineering Company; and Micropipettes (0o05 ml volume), obtained from 
Microbiological Associates, Bethesda, Maryland. 
The Falcon Microtest II tissue culture plate has 96 wells in 
an 8 by 12 arrangement. Using a 0,05 ml micropipette, in which each 
drop is calibrated at 0.05 ml, one drop of MEM with 3% calf serum was 
added to each well. Appropriate serial 10-fold dilutions of virus 
in quadruplicate were diluted with a 0<,05 ml microdlluter in three 
step 2-fold series. Three dilutions of each sample were plated. 
The microdlluter was dipped in 95% ethanol and rotated 
_3 
between the fingertips. After flaming, and starting with the 10 
dilutiont an entire sanqple was plated before sterilizing the microdl­
luter again. A diagramniatic representation of the tissue culture 
plate is shown in Figure 1. 
The microdlluter was allowed to cool for about 15 seconds, then 
3 
dipped into the 10 dilution. The microdlluter was rotated for 10 
cycles back and forth with the fingertips, then placed into the 2 
well in the extreme right of the 10 ̂  series and rotated for 10 
cycles. The microdlluter was removed from the 2 ̂  well, placed into 
the 2 well, and rotated for 10 cycles. The microdlluter was 
-2 -3 
removed from the 2 well, placed into the 2 well, and rotated for 
10 cycles. Finally, the microdlluter was removed from the last well 
and reloaded in the 10 dilution. The above was repeated until the 
Hliçrotiter is a trademark of Cooke Engineering Company of 
Alexandria, Virginia. 
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three dilutions were plated, the microdlluter was sterilized in alcohol 
and flamed, and the next sample was started. The process was made 
faster when two or more mlcrodlluters were used simultaneously. 
With dilutions in test tubes, two mlcrodlluters was the practical 
limit. When all samples were plated, 0.05 ml of a suspension of 
2 X 10̂  Vero cells per ml of MEM plus 3% calf serum was added to each 
3 
well, or 1 X 10 cells per well. The plates were read at 48 hours by 
noting the presence of absence of CPE in the monolayers in the well. 
10"̂  10"̂  10~3 
Sample #1 $ e 4 e 0 0 0 0 
-®- -e- «- -®- 0 0 0 0 0 
e- •©•-©• -®- 0 0 0 0 0 0 0 0 
Controls 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 
Sample #2 $- -e- # MB- # 0 0 0  0 0 0 0 
0 0 0 0 0 0 0 0 
# $ # 0 0 0 0 0 0 0 0 0 
Figure 1. Diagrammatic Representation of a Mlcrotest II Plate 
To calculate the TCID̂ Q, the Reed-Muench formula was modified 
from the original described by Lennette and Schmidt (15). Data was 
arranged according to Table 4 (e.g., Sample 1, from Figure 1). 
The accumulated values for the number of wells showing CPE 
(column e) or not showing CPE (column f) are obtained by adding 
columns c and d in the direction indicated by the arrows. The 
accumulated mortality ratio (column g) represents the accumulated num­
ber of wells showing CPE (column e) over the total number of wells 
2 
accumulated (column e + column f). For example. In the 4 x 10 reci­
procal of the virus (RV) dilution, there were three wells showing CPE 
in a total of four wells. 
2 
In the example, the percentage CPE in the 4 x 10 RV dilution 
2 
la higher than 50%; the percent CPE in the next RV dilution, 8 x 10 , 
is lower than 50%. The 50% endpoint lies between these two RV dilutions. 
The proportionate distance of the 50% endpoint from the 
dilution next above 50% is obtained as follows : 
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Proportionate. '̂ %r.boL1on 
Distance 
(Percent CPE at RV dil, _ (Percent CPE at RV dil, 
next above 50%) next below 50%) 
75 - 50 
7 5 - 0  
25 
75 
0.33 
Since logarithmically the distance between any two dilutions 
is a function of the Incremental steps used in preparing the series, 
it is necessary to correct (i.e., multiply) the proportionate distance 
by the logarithm of the dilution factor. In a 2-fold dilution series, 
the logĵ Q(2) • .301 is used as the correction factor. Therefore: 
(The logarithm of the RV dilution next 
The logarithm of the TCID̂ Q ̂  above 50% CPE) 
endpoint titer + 
(The proportionate distance multiplied 
by the logarithm of the dilution 
series used) 
or 
[logiQ(4 X 10̂ )] + [(0.33)(logio(2))] 
[(0.33)(.301)] 
11 
[2,602] + [0.100] - 2.702 
Since the volume of the culture fluid sample is 0.05 ml, the 
[iGĝ Q(TCID̂ g)] = [2.702/0.05 ml] 
[TCID^Q] = [5.4 X 10̂  units/0.05 ml] 
= [1.08 X 10̂  units/ml] 
= [1.1 X 10̂  units/ml] 
In cases such as Sample #2 in Figure 1, where the RV dilution 
1 2 
next above 50% is 8 x 10 , and the next below 50% is 2 x 10 , which is 
18 
12 1 
not a 2-fold increment, the average of 8 x 10 and 1 x 10 , or 9 x 10 , 
was used to minimize error. 
Table 4. Data Arrangement for Reed-Muench Formula 
Reciprocal 
CPE 
Ratio 
Accumulated Values 
of Virus CPE No CPE 
CPE No CPE 
Mortality 
Dilution Ratio Percent 
a b c d e f 8 h 
2 X 10^ 4/4 4 0 19 0 19/19 100 
4 X 10^ 4/4 4 0 15 0 15/15 100 
8 X 10^ 4/4 4 0 11 0 11/11 100 
2 X 10^ 4/4 4 0 7 0 7/7 100 
4 X 10^ 3/4 3 1 ' i 3 1 3/4 75 
8 X 10^ 0/4 0 4 0 5 0/5 0 
2 X 10^ 0/4 0 4 0 9 0/9 0 
4 X 10^ 0/4 0 4 0 13 0/13 0 
*The reciprocal of the virus dilution is abbreviated as the RV 
dilution in this procedure. 
Cells 
The cells used for this experimental series were Vero, HeLa, and 
MAlll. The few laboratory rabbits available for this study carried a 
vacuolating virus which appeared about 72 hours or more after their 
kidney cells were cultured. Because of this and other difficulties, 
primary rabbit kidney cultures were not included in the study. 
The Vero cell line was derived from a culture from an African 
Green monkey kidney line by Yasumura and Kawakita (1). The HeLa line 
originated from a human carcinoma of the cervix and was established 
by Gey, et al. (9). The MAlll line is a stable rabbit kidney line 
stabilized after numerous passages by Vincent (29). 
The MAlll line was received from Microbiological Associates 
in Medium 199 and 10% fetal calf serum. It was transferred to MEM 
with 10% calf serum and adapted to MEM with 5% calf serum which was 
the standard medium used to grow stock cultures of stable cell lines. 
On Initial passages, MAlll was split 1:2 as recommended by Microbiolo­
gical Associates. It was found that cells could be split 1:5 on clean 
glass and 1:10 on "used" glass, as was standard procedure for Vero 
and HeLa cells. Used glass is glassware that was used for growing 
cells and which has not been reprocessed. Glassware was used until 
the cells began sticking to the glass during passage. 
The cells lines, which were grown in 8 oz. prescription bottles, 
were passed by trypsinization of monolayers and reseeding part of the 
cells. Prior to the addition of 1 ml of versene-trypsin solution to 
each bottle, the monolayer was washed twice with about 5 ml of Pd, 
incubated in 10 to 15 ml of Pd for 5 minutes, and washed once more 
with 5 ml Pd. The Pd wash served to remove Mg and Ca ions and 
any other serum factors which inactivate trypsin. When the cells 
detached from the glass (5 to 10 minutes), the suspension was mixed 
with 10 ml of growth medium. For maintaining stock cultures, 1 to 
2 ml of this cell suspension was left in each bottle and 20 ml of 
fresh MEM with 5% calf serum was added to each bottle. 
Cells seeded on clean glass were gassed with air containing 5% 
COg to complete the Earle's HCO^ /COg buffer used in MEM. Cells seeded 
on used glassware generate sufficient CO^ to complete this buffer. 
Microtest plates were placed in a gas-tight box which was gassed with 
air with 5% COg. The temperature of incubation for growing cells and 
for conducting the growth curve studies was 37°C. 
When known numbers of cells were desired, the cells were 
counted by using a hemocytometer. A hemocytometer has a grid of 16 
2 
large squares measuring 1 mm . A glass coverslip restricts the chamber 
3 
depth to 0.1 mm. Therefore, each square represents 0.1 mm of cell 
suspension. The cells are counted in the 4 comer squares which are 
in turn subdivided into 16 smaller squares for ease of counting. The 
total number of cells in the 4 sqaures is divided by 4 to get the 
3 3 3 
average cell count per 0.1 mm . There are 1000 mm per 1.0 cm , and 
3 
1.0 cm is approximately 1.0 ml. Therefore, the average cell count 
3 4 
per 0.1 mm multiplied by 10 is a good estimate of the number of 
cells per ml. Needless to say, if any other dilutions are made before 
the cell count is taken, they must be considered in the calculations. 
CHAPTER III 
RESULTS 
For the growth curve studies, 3 oz. prescription bottles were 
seeded with 5 x 10^ cells on 10 to 12 ml of MEM with 5% calf serum. 
The cells were allowed to grow monolayers of 4 x 10^ cells as 
determined by trypsinizing random cultures and counting the cells in 
a hemocytometer. The monolayers were infected with 1.6 to 2.0 x 10^ 
TCID^Q units of HVH type 2 (strain 196) in 1.0 ml medium. The virus 
was adsorbed for 60 minutes at 37°C. After the adsorption period the 
cultures were washed three times with 10 ml Fd to remove unadsorbed 
virus. Finally, 8 ml of MEM with 3% calf serum was added to the 
cultures. The saiiq>les taken at this time were plotted at Time = 0. 
Released virus was sampled by adding 0.5 ml of MEM with 3% 
calf serum to the culture, mixing, then removing 0.5 ml of culture 
fluid. Total virus was sampled by freezing and thawing the culture 
three times to disrupt the cells and to release cell-associated 
virus. If released and total virus were sampled simultaneously from 
the same culture, the released virus sample was taken as above prior 
to freezing the culture. All samples were assayed for virus by the 
TCIDgg method described in the Materials and Methods section. 
The growth curves of HVH type 2 in all three cell lines were 
superficially similar to each other although different in detail. All 
showed latent periods where the residual virus titer fell. After 
sufficient time to initiate assembly of virus, the titers rose, passing 
quickly into log growth phase. Foci of CPE appeared toward the end 
of the latent period. Finally, there were decelerated growth and 
terminal growth phases. All cells had detached from the glass sur­
face by the end of the decelerated growth phase. During the terminal 
phase the virus was not being replicated, but cell-associated virus 
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was released slowly as the cells broke up due to autolysis. 
For Vero cells (Table 5, Figure 2), the latent period for 
total virus was about three hours. After four hours the titer had 
risen and replication was In log phase. Between twelve and fourteen 
hours replication had slowed, and by sixteen hours terminal phase 
was reached. The latent period for virus release was about four hours. 
Release reached log phase by six hours, slowed by twenty hours and was 
terminal by twenty-four hours. The peak total virus titer was about 
1.6 X 10^ TCID^Q units per ml of culture fluid. The peak titer of 
virus released was about 5.2 x 10^ TCID^Q units per ml of culture fluid. 
Peak titer was determined by taking the mean of the titer of all 
samples taken after terminal phase was reached. 
For HeLa cells (Table 6, Figure 3), the latent period to 
total virus replication was about four hours. After six hours the 
titer had risen and replication was in log phase. By twenty hours 
replication had slowed, and by twenty-four hours replication was in 
terminal phase. The latent period for virus release was about four 
hours. After six hours the titer had risen and release was in log 
phase. The release slowed between eighteen and twenty hours and was 
terminal by twenty-four hours. Peak total virus titer was about 
7 X 10^ TCID^Q units per ml of culture fluid. Peak released virus titer 
was about 3.0 x 10^ TCID^Q units per ml of culture fluid. 
For MAlll cells (Table 7, Figure 4), the latent period for 
total virus replication was about six hours. Log phase was reached 
shortly after eight hours. Replication slowed by eighteen hours and 
was terminal by twenty hours. The latent period for virus release 
was about nine hours. Log phase was reached by twelve hours. Release 
slowed by eighteen hours and was terminal by twenty hours. Peak total 
5 
virus titer was about 8.1 x 10 TCIDrn units per ml of culture fluid. 50 
Peak released virus titer was about 1.1 x 10 TCID^Q units per cell. 
Herpesvirus hominls type 2 (strain 196) tended to remain 
cell-associated in all three cell lines, as Indicated by the differences 
between total and released virus titers. In Vero cells 67.5% of the 
virus remained cell-associated; in MAlll cells 87.3% of the virus 
remained cell-associated. In HeLa cells 57% of the virus remained 
cell-associated. 
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A thermal stability test at 37°C was conducted by suspending 
an ampule of stock virus in a total of 10 ml of MEM with 3% calf serum 
in a screw capped test tube. At desired times, 0.5 ml of virus sus­
pension was removed and assayed by the TCID^Q method. The tube was 
gassed with air plus 5% CO^ each time it was opened to maintain pH 7. 
It was found (Figure 5) that after a relatively stable period 
of about five hours the virus became unstable. About 70% of the virus 
was lost in ten to twelve hours and about 95% of the virus was lost 
in twenty-four hours. By extrapolation, the half-life of HVH type 2 
was about eight hours. 
Freeze-thaw stability was determined by suspending stock virus 
in 10 ml of MEM with 3% calf serum. A dry ice-alcohol bath was used 
to freeze the sample, and warm water was used to thaw it. The screw 
capped test tube was gassed with air each time it was opened to 
flush the COg which entered the tube from the dry ice bath. After 
each freeze-thaw cycle 0.5 ml of the virus suspension was removed and 
assayed by the TCID^Q method. 
The freeze-thaw stability test (Figure 6) showed a slight rise 
in titer after the first cycle, then a stable period of two cycles, 
followed by loss of virus on subsequent cycles. Half the peak titer 
of virus was lost by the seventh cycle. 
A trial was conducted to verify that release of virus by 
cells after they detach from the culture surface were passive (i.e., 
that the cells were dead and virus was released when the cells dis­
rupted due to autolysis). A 3 oz, prescription bottle containing 
4 X 10^ cells was infected with 2 x 10^ TCID^Q units of virus by the 
same methods used in the growth curve studies. After twenty-two hours 
the detached cells were pelletted at low speed (1,000 rpm in an 
International H9070 centrifuge). The cells were washed twice by 
resuspending them in 10 ml MEM with 3% calf serum and 1.0 ml samples 
were removed, after gently rocking the tube to resuspend the cells 
at two-hour intervals for six hours. Of the sample, 0.5 ml was 
used to assay for released virus by the TCID^Q method, and the balance 
was used to make cell counts in a hemocytometer. 
The trial (Table 8) shows a slight increase in released virus 
23 
titer accompanied by a slight loss in cell count, suggesting that virus 
was released from the detached cells as the cells were disrupted by 
autolysis. 
Table 9 shows the peak total and released virus titers 
expressed as yield per cell In the infected monolayer. This comparison 
makes it possible to relate this study with those in the literature. 
These data were calculated by taking the average yields per ml of cul­
ture fluid, and dividing by 4 x 10^ cells. Vero cells released 1.1 
TCID^Q units per cell and produced 3.2 TCID^^ units per cell. HeLa 
cells released 0.6 TCID^Q units per cell and produced 1.4 TCID^Q units 
per cell. MAlll cells released 0.22 TCID^q units per cell and pro­
duced 1.6 TCID^Q units per cell. 
24 
Table 5. Herpesvirus hoïïilnls type 2 (strain 196) Replication in a 
Monolayer of 4 x 10^ Vero Cells in 8 ml Minimal Essential Medium with 
3% Calf Serum: Infective Dose 1.6 to 2.0 x 10 TCID ̂  Units; Incubation 
Temperature 37 C. 
* 
Time 
Released Total 
Trial 1 Trial 2 Trial 1 Trial 2 Trial 3 
0 1.6 X 10^ 2.3 X 10^ 8.0 X 10^ 5.5 X 10^ 2.3 X 10^ 
3 8.0 X 10^ —— — 1.4 X 10^ ——— 
4 —— — 1.1 X 10^ — 5.6 X 10^ 
6 1.1 X 10^ ——— 4.0 X 10^ 2.3 X 10* — — 
8 ——— 2.0 X 10^ 2.0 X 10^ —' 1.6 X 10^ 
9 5.7 X 10^ ——— 
2.3 X 10^ 
1.6 X 10^ ——— 
12 1.6 X 10^ 6.4 X 10^ 4.0 X 10^ 1.4 X 10^ 
15 1.0 X 10^ ——— 8.0 X 10^ —— 
16 6.8 X 10^ — ——— 1.3 X 10^ 
18 1.1 X 10^ ——— ——— 8.0 X 10^ ——— 
20 ——— 2.0 X 10^ ——— — — 2.3 X 10^ 
21 5.7 X 10^ ——— 6.4 X 10^ 5.7 X 10^ ——— 
24 8.0 X lof 3.6 X 10^ 6.4 X 10^ 2.5 X 10^ 
28 ——— 4.5 X lof —— — ——— 1.4 X 10^ 
Time expressed in hours. 
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Figure 2. Herpesvirus hominis type 2 (strain 196) Replication in a 
Monolayer of 4 x 10 Vero Cells in 8 ml Minimal Essential Medium With 
3% Calf Serum; Infective Dose 1.6 to 2.0 x 10^ TCID _ Units; Incubation 
Temperature 37 C. 
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Table 6. Herpeavlrua homlnla type 2 (strain 196) Replication in a 
Monolayer of 4 x 10^ HeLa Cells in 8 ml Minimal Essential Medium With 
3% Calf Serum; Infective Dose 1.6 to 2.0 x 10^ TCID^Q Units; Incubation 
Temperature 3/ C 
* 
Time 
Released Total 
Trial 1 Trial 2 Trial 1 Trial 2 
0 6 . 0  X  1 0 ^  3 . 6  X  10^ 4 . 7  X  1 0 ^  1 . 6  X  1 0 ^  
3 2 . 0  X  1 0 ^  — — — —  — —  
4 2 . 0  X  10^ 5 . 7  X  1 0 ^  
6 3 . 0  X  1 0 ^  — 8 . 0  X  1 0 ^  
8 — — —  5 . 0  X  10^ — — —  2 . 5  X  1 0 ^  
9 1 . 4  X  1 0 *  —  —  —  — —  —  
12a** 3 . 6  X  1 0 ^  1 . 1  X 10^ 1 . 6  X  1 0 ^  5 . 7  X  1 0 ^  
12b** 2 . 0  X  1 0 *  — 9 . 3  X  1 0 ^  — — —  
15 2 . 5  X  1 0 *  — — — —  
16 — — —  1 . 0  X 10^ 2 . 9  X  1 0 ^  
18 5 . 6  X  1 0 ^  — 2 . 6  X  1 0 ^  — — —  
20 — — —  5 . 7  X 10^ — — —  2 . 2  X  1 0 ^  
21 1 . 0  X  1 0 ^  — —  — — —  
24 2 . 1  X  1 0 ^  4 . 4  X 10^ 2 . 0  X  1 0 ^  1 . 1  X 10^ 
28 — — —  2 . 5  X 10^ 8 . 0  X 10^ 
*Time expressed in hours. 
**The growth curve was split at 12 hours. T = 12a was the end 
of one half, and T = 12b was the start of the other half. 
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Figure 3. Herpesvirus hominls type 2 (strain 196) Replication in a 
Monolayer of 4 x 10 HeLa Cells in 8 ml Minimal Essential Medium With 
3% Calf Serum; Infective Dose 1.6 to 2.0 x 10° TCID^g Units; Incubation 
Temperature 37°C 
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Table 7. Herpesvirus hominis type 2 (strain 196) Replication in a 
Monolayer of 4 x 10 MAlll Cells in 8 ml Minimal Essential Medium With 
3% Calf Serum; Infective Dose 1,6 to 2.0 x 10 TCID^» Units: Incubation 
Temperature 37°C 
* 
Time 
Released Total 
Trial 1 Trial 2 Trial 1 Trial 2 
0 1 . 1  X  1 0 ^  6 . 4  X  1 0 ^  7 . 7  X  1 0 ^  2 . 0  X  l ( f  
3 4 . 0  X  1 0 ^  —  — —  —  
4 — 3 . 0  X  1 0 ^  6 . 8  X  1 0 ^  
6 3 . 0  X  1 0 ^  — — 2 . 0  X  1 0 ^  
8 2 . 3  X  1 0 ^  —  4 . 5  X  1 0 ^  
9 
12a** 
12b** 
2 . 5  X  1 0 ^  
8 . 0  X  1 0 ^  
4 . 5  X  1 0 ^  
5 . 0  X  1 0 ^  6 . 4  X  1 0 ^  
2 . 2  X  1 0 ^  
3 . 0  X  l o ' ^  
15 1 . 6  X  1 0 ^  — —  —  
16 1 . 6  X  1 0 ^  — 2 . 0  X  1 0 ^  
18 8 . 0  X  1 0 ^  1 . 3  X  1 0 ^  
20 9 . 3  X  1 0 ^  4 . 7  X  1 0 ^  
21 8 . 0  X  1 0 ^  — — —— —  —— —  
24 1 . 3  X 105 1 . 6  X 10^ 1 . 6  X 10^ 5 . 7  X 10^ 
28 —  —  —  1 . 8  X 10^ 6 . 4  X 10^ 
Time expressed in hours. 
The growth curve was split at 12 hours. T = 12a was the end 
of one half, and T = 12b was the start of the other half. 
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Figure 4. Herpesvirus hominis type 2 (strain 196) Replication in a 
Monolayer of 4 x 10^ MAlll Cells in 8 ml Minimal Essential Medium With 
3% Calf Serum; Infective Dose 1.6 to 2.0 x 10 TCID^Q Units; Incubation 
Temperature 37°C 
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Figure 5. Thermal Stability of Herpesvirus homlnls type 2 (strain 196) 
at 37°C 
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Figure 6. Freeze-Thaw Stability of Herpesvirus homlnls tyrae 2 (strain 
196) 
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Table 8. Extended Release of Herpesvirus homlnls type 2 (strain 196) 
by Detached Vero Cells in 10 ml Minimal Essential Medium With 3% 
Calf Serum; Incubation Temperature 37°C 
Time in Hours TCID^Q of Released Virus Cell Count 
0 6.36 X 10^ units/ml 7 x 10^/ml 
2 6.36 X 10^ units/ml 5 x 10^/ml 
4 6.00 X 10^ units/ml 6 x 10^/ml 
6 8.00 X 10^ units/ml 5 x 10^/ml 
Table 9. Peak Herpesvirus hominis type 2 (strain 196) Titers in 
Different Stable Cell Lines Expressed in Terms of TCID^Q Units pe 
in the Infected Monolayer; Incubation Temperature 37°C 
Cell Line Released Virus Titer Total Virus Titer 
Vero 
HeLa 
MAlll 
1.10 
0 .60  
0 . 2 2  
3.2 
1.4 
1.6 
CHAPTER IV 
DISCUSSION 
There appears to be no precedent in the literature for dis­
cussing the Vero or MAlll culture and HVH systems. Both cell lines 
have been used extensively for the study of RNA viruses (26, 27) and 
to some extent with SV-40 and adenoviruses (29). This study indicated 
that Vero was superior to HeLa cells in its capacity to support the 
reproduction of HVH type 2. Vero was also found to be superior to 
HeLA as an indicator cell for the assay of HVH type 2 because it 
showed CPE sooner than HeLa, espeically under low multiplicity con­
ditions, Furthermore, in pilot studies, it was found that Vero could 
be maintained in monolayer for longer periods of time than HeLa. The 
MAlll cell line was at least equal to HeLa in its capacity to support 
HVH type 2 reproduction, but it was not equivalent to primary rabbit 
kidney cells as it was hoped to be. The initial observations which 
prompted this study indicated that primary rabbit kidney did not 
support the growth of HVH type 2 as well as HeLa did. 
There has been extensive work with the HeLa and HVH system, and 
some growth curve data has been published. Waterson (1968), summa­
rizing a paper by Newton and Stoker (1958), reports that HeLa pro­
duced 10 plaque-forming units per cell. Siminoff (1964), working 
with two strains of HVH, reports yields of 16 and 50 plaque-forming 
units per cell. In both studies 5 plaque-forming units per cell were 
used as initial inocula. The differences in yield of this study 
compared to yields reported in the literature are probably due to a 
combination of initial infective dose, strain differences in the virus, 
and to the relative sensitivity of the assay methods. 
The stability tests (Figures 5 and 6) compared closely with 
those done by Kaplan (1957). He reports less than 1% survival of his 
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H-4 strain of HVH after 24 hours at 37°C. In this study, HVH type 2 
(strain 196) had a survival rate of less than 5% after 24 hours. 
Kaplan's freeze-thaw material shows a rise in titer that he attributes 
to disruption of virus aggregations, a stable period of two or three 
freeze-thaw cycles, and finally, loss of virus on subsequent cycles. 
The results of this study (Figure 6) show a similar pattern, with 
50% loss by cycle 7 and 70% loss by cycle 9. After the first three 
cycles, roughly 10% loss of virus titer can be expected with each 
subsequent freeze-thaw cycle. 
This Study showed different growth patterns in the different 
cell lines. The log growth phase in both Vero and MAlll had a 
steeper slope than did the log phase of HeLa. As mentioned in the 
introduction. Group A viruses show changes in virulence when intro­
duced into unnatural hosts. Herpesvirus hnmin1a infection in man is 
usually mild, but in the absence of immune mechanisms the virus is 
able to infect all the cells in the culture. The steeper slopes 
of the log growth phases of Vero and MAlll and their subsequent earlier 
death may indicate part of the reason for the severity of HVH infection 
in monkeys and rabbits. The virus had a longer latent period in 
MAlll than in either Vero or HeLa. Since rabbits are not as phylogene-
tically close to humans as monkeys, HVH may not be able to use the 
enzyme systems present in rabbit cells as efficiently as it uses the 
enzyme systems in human or monkey cells. After the latent period, 
virus-coded enzymes play a more important role in the infection (8, 14). 
Once the virus-coded enzyme systems are established, there are no 
genetic factors, as found in human cells, to retard the infection in 
either Vero or MAlll. 
Initial trials showed that the released virus titer remained 
stationary for about 48 hours before falling. It was presumed that 
cell-associated virus was being released from the detached cells at a 
rate to compensate for thermal lability. Detached Vero cells resus-
pended in fresh MEM plus 3% calf serum showed a slight rise in virus 
titer and a slight loss In cell count (Table 6). The growth curve 
studies showed the presence of a viable cell-associated virus which is 
released when the cells are disrupted. This test verified a slight 
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rise in virus titer with a slight loss in cell count. This study was 
conducted within the time limit of the stable period in the viral 
thermal lability curve, and the cells were put under more stress for 
this test than in the pilot growth curve studies when they were not 
pelletted and resuspended. All factors considered, it is feasible that 
enough virus was cell-associated and could be released by cell 
break-up due to autolysis to keep the released virus titer relatively 
stable. Pilot studies with Vero also showed that the total virus titer 
fell within 36 hours. From the above, it can be concluded that 
detached cells are dead and are no longer replicating virus. 
In all three cell lines, ballooning and detaching of cells 
seemed to be directly related to virus production; as more cells 
ballooned, more virus was detected. All cells in all three cell 
lines detached within 18 to 24 hours, Vero being the first to detach 
completely and HeLa and MAlll detaching later. 
In the preparation of stock pools, it was noted that most 
HeLa cells detach from the glass culture surface after 48 to 60 hours. 
Vero cells detach after 26 to 30 hours. Since virus production seems 
to be related to the appearance of CPE, the lower titers observed in 
HeLa are probably a result of the slower rate of virus replication in 
HeLa, the resultant lower peak titer, and to thermal inactivation of 
the virus at 37°C. 
CHAPTER V 
SUMMARY 
It was noted by Dr. R. N. Ushijlma that when Herpesvirus hominis 
was prepared in different cell lines, there were differences in peak 
titers of virus produced. It was decided to do growth curve studies to 
determine the rate and time of release of HVH type 2 (strain 196) from 
the cell lines, HeLa, Vero, and MAlll, and to correlate, if possible, 
the appearance of CPE with the production of virus. Stability tests 
were done; a determination of the viability of detached cells was 
done. 
Monolayers of 4 x 10^ cells in 3 oz. prescription bottles were 
infected with 0.5 TCID^Q units of virus. The cultures were sampled 
for total and released virus. The virus was assayed by the Micro-
titer^ method, and the 50% Tissue Culture Infective Dose (TCID^Q) 
was calculated by a modified Reed-Muench method. 
Cell-free virus was resuspended in MEM with 3% calf serum, and 
the virus was tested for stability at 37°C and for stability when 
exposed to repeated freeze-thaw cycles. 
Detached infected Vero cells were pelletted and resuspended 
in fresh MEM. Virus assays and cell counts were done at two-hour 
intervals for six hours. 
The growth pattern of HVH was different in each cell line. 
With respect to total virus, the latent period in Vero was about 3 
hours, in HeLa about 4 hours, and in MAlll about 7 hours. Peak titers 
were produced in 14 hours by Vero, in 24 hours by HeLa, and in 16 
hours by MAlll, The virus tended to stay cell-associated in all cell 
lines. In Vero, 67.5% of the virus remained cell-associated, and in 
HeLa 57% of the virus remained cell-associated; 87.3% of MAlll virus 
^Trademark of Cooke Engineering Co., Alexandria, Virginia. 
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remained cell-associated. The virus remained cell-associated for a 
relatively longer time in MAI11 than in Vero or HeLa. Cytopathic 
effect appeared in foci at the end of the latent period, and all Cells 
had detached by the time peak titers were produced. 
Peak total virus titers were 3.2 TCID^Q units per cell for 
Vero, 1.4 TCIDgg units per cell for HeLa, and 1.6 TCID^Q units per 
cell for MA.111. Peak titers for released virus were 1.1 TCID^Q units 
per cell for Vero, 0.6 TCID^Q units per cell for HeLa, and 0.22 TCID^Q 
units per cell for MAlll. 
Both the thermal stability test and the freeze-thaw stability 
test showed brief stability followed by lability. The virus was 
stable for about five hours at 37°C and over three freeze-thaw cycles. 
The half-life of the virus at 37°C was about eight hours, and half 
the virus titer was lost after seven freeze-thaw cycles. 
It was concluded that detached cells were dead and released 
cell-associated virus passively as they broke up due to autolysis. 
It was also concluded that the lower peak titers produced 
in HeLa with respect to Vero when stock pools were prepared were a 
function of the slower replication rate in HeLa and the lower peak 
titer produced by HeLa reduced further by thermal inactivation of the 
virus. 
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APPENDIX 
PARTIAL LIST OF SUPPLY COMPANIES 
Bellco Glass Company, Inc. 
340 Edrudo Road 
Vlneland, New Jersey 08360 
Bloquest 
P.O. Box 243 
Cockeysville, Maryland 21030 
Calblochem 
P.O. Box 12087 
San Diego, California 92112 
Cole-Parmer Instrument Company 
745 North Oak Park Avenue 
Chicago, Illinois 60648 
Cooke Engineering Company 
Medical Research Division 
735 N. St. Asaph Street 
Alexandria, Virginia 22314 
Coming Glass Works 
Laboratory Products Division 
Coming, New York 14380 
Dlfco Laboratories 
P.O. Box 5058A 
Detroit, Michigan 48232 
Flow Laboratories 
1710 Chapman Avenue 
Rockville, Maryland 20852 
Grand Island Biological Company (GIBCO) 
3175 Stanley Road 
Grand Island, New York 14072 
Kimble Products, Division of Owens-Illinois 
Toledo, Ohio 43601 
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Miles Laboratories, Inc, 
Research Division 
P.O. Box 272 
Kankakee, Illinois 60901 
Microbiological Associates 
4733 Bethesda Avenue 
Bethesda, Maryland 20014 
Sargent-Welch Scientific Company 
7300 North Linder Avenue 
Skokie, Illinois 60076 
Van Waters and Rogers Scientific Company 
P.O. Box 320 
San Francisco, California 94119 
or 
P.O. Box 23 
High Brdge Station 
Bronx, New York 10452 
